These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26231466)

  • 1. Economic realities and the health plight of Americans.
    Wolf BL
    Ann Allergy Asthma Immunol; 2015 Sep; 115(3):170-1. PubMed ID: 26231466
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacoeconomic aspects of bronchial asthma].
    Prosekova EV; Gel'tser BI; Shestovskaia TN
    Ter Arkh; 2000; 72(3):55-8. PubMed ID: 10776656
    [No Abstract]   [Full Text] [Related]  

  • 3. U.S. asthma drug costs to jump 50% by 2023.
    Manag Care; 2014 Oct; 23(10):49. PubMed ID: 26023688
    [No Abstract]   [Full Text] [Related]  

  • 4. Caveat emptor.
    Wolf BL
    Ann Allergy Asthma Immunol; 2009 May; 102(5):443. PubMed ID: 19492671
    [No Abstract]   [Full Text] [Related]  

  • 5. Pediatric asthma.
    Mueller HP; Fischer W; Cave DG
    Manag Care Interface; 1999 Oct; 12(10):44-6. PubMed ID: 10623005
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of Biological Agents in Asthma: Pharmacoeconomic Lessons Learned From Omalizumab.
    Draikiwicz S; Oppenheimer J
    Chest; 2017 Feb; 151(2):249-251. PubMed ID: 28183482
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacoeconomics of asthma].
    Jahnz-Rózyk K; Targowski T
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():48-9. PubMed ID: 15524016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pressure point. When coughing up is essential.
    Cooper C
    Health Serv J; 2000 Nov; 110(5733):suppl 1. PubMed ID: 11138527
    [No Abstract]   [Full Text] [Related]  

  • 9. Revisiting the cost-effectiveness of omalizumab.
    Campbell JD; Spackman DE; Sullivan SD
    Allergy; 2007 Dec; 62(12):1469. PubMed ID: 17983382
    [No Abstract]   [Full Text] [Related]  

  • 10. [How to make easier the treatment of asthma].
    Ait-Khaled N
    Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S76-10S79. PubMed ID: 17127972
    [No Abstract]   [Full Text] [Related]  

  • 11. [Analyzing the economy, something is changing concerning asthma].
    Serra Batlles J
    Arch Bronconeumol; 2009 Oct; 45(10):475-7. PubMed ID: 19758739
    [No Abstract]   [Full Text] [Related]  

  • 12. [Geographic and economic aspects of inhalation therapy].
    Haidl P; Köhler D
    Pneumologie; 1999 Dec; 53(12):612-6. PubMed ID: 10684240
    [No Abstract]   [Full Text] [Related]  

  • 13. The relationship between pharmaceutical costs, disease severity, and health-related quality of life in asthmatics in Swedish primary care.
    Arnlind MH; Nokela M; Rehnberg C; Jonsson EW
    J Asthma; 2006 Oct; 43(8):585-91. PubMed ID: 17050222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to Campbell, Spackman, Sullivan letter to Allergy.
    Brown R; Turk F; Dale P; Bousquet J
    Allergy; 2008 Jun; 63(6):783. PubMed ID: 18445194
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharma focus. Puff adders.
    Chapman S
    Health Serv J; 2003 Nov; 113(5883):suppl 6-7. PubMed ID: 14671867
    [No Abstract]   [Full Text] [Related]  

  • 16. Budget busters.
    Cresswell J
    Community Nurse; 1999 Oct; 5(9):10. PubMed ID: 10732567
    [No Abstract]   [Full Text] [Related]  

  • 17. Need to lobby for access to asthma medications.
    Silversides A
    CMAJ; 2007 Apr; 176(9):1263-4. PubMed ID: 17452654
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceutical costs. An overview and analysis of legal and policy responses by the states.
    Latham SR
    J Leg Med; 2003 Jun; 24(2):141-73. PubMed ID: 12775406
    [No Abstract]   [Full Text] [Related]  

  • 19. Final report regarding asthma adherence.
    Weinstein AG; Feldstein J; Esterly K
    Del Med J; 2001 Sep; 73(9):341-5. PubMed ID: 11668907
    [No Abstract]   [Full Text] [Related]  

  • 20. Eliminated patient fee and changes in dispensing patterns of asthma medication in children-An interrupted time series analysis.
    Dahlén E; Komen J; Jonsson EW; Almqvist C; Kull I; Wettermark B
    Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):360-369. PubMed ID: 31188534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.